A phase II trial of docetaxel, cisplatin, irinotecan and bevacizumab (TPCA) in metastatic esophageal and gastric cancer
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin; Docetaxel; Irinotecan
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 09 May 2016 Planned End Date changed from 1 Dec 2014 to 1 Jun 2016.
- 07 Aug 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.